ROSELAND, N.J., March 26, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide objective, pressure-guided precision, today announced that it will host a conference call at 8:30 AM Eastern Time on Wednesday, April 1, 2026, to discuss the company’s financial results for the fourth quarter and full year ended December 31, 2025, as well as the company’s corporate progress and other developments. The conference call will be av ...

ROSELAND, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide objective, pressure-guided precision, today announced the launch of the CompuFlo® Advisor Program. This strategic initiative is designed to drive mainstream commercial adoption, increase recurring disposable revenue, and generate the clinical data necessary to optimize long-term Medicare reimbursement rates. The program, which commenced on Febru ...

Core Insights - Milestone Scientific Inc. has launched The Wand® Ambassador Program to enhance clinical awareness and adoption of The Wand® STA System in the dental market [1][6] Group 1: Program Overview - The Ambassador Program is a peer-to-peer initiative that utilizes experienced dental professionals to share clinical insights and experiences, aiming to foster engagement with potential practices [2] - The pilot of the program began on December 8 with six dental professionals in select U.S. markets, receiving positive feedback and interest from additional practitioners [3] Group 2: Expansion Plans - Milestone plans to scale the program to approximately 250 dental professionals within the next 12 months, supported by structured onboarding and educational resources [4] - The program includes tools for real-time visibility into engagement activities, allowing the company to measure effectiveness and optimize execution [4] Group 3: Expected Outcomes - Based on early pilot results, Milestone anticipates a 2-3x increase in product demonstrations, which will enhance demo-to-sales conversion efficiency [5] - The Ambassador Program is expected to strengthen market awareness and support broader adoption of The Wand STA system, contributing to sustainable growth [6] Group 4: Leadership Perspective - CEO Eric C. Hines expressed optimism regarding the early response to the program, highlighting its potential to increase product demonstrations and reinforce clinical confidence [7]

Financial Data and Key Metrics Changes - For Q3 2025, revenue was $2.4 million, a slight decrease from $2.5 million in Q3 2024. For the nine months ended September 30, 2025, revenue was $6.9 million, compared to $6.6 million for the same period in 2024 [10] - Gross profit for the nine months ended September 30, 2025, was approximately $4.9 million, reflecting no material year-over-year change [10] - Operating expenses were approximately $1.1 million for Q3 2025, down over $500,000 compared to the same period last year [5][10] Business Line Data and Key Metrics Changes - In the dental segment, international sales increased year-over-year, partially offsetting a decline in domestic revenue [7] - Utilization of CompuFlow disposables rebounded slightly, indicating a re-engagement with current customers [7] Market Data and Key Metrics Changes - The company has a market share of approximately 1.5%-2% in both domestic and international markets, indicating significant room for growth [16] Company Strategy and Development Direction - The company is focused on three strategic priorities: streamlining operations, strengthening commercial execution in dental and medical sectors, and advancing reimbursement strategies for CompuFlow [6][8] - The addition of Dr. Dawood Syed to the board aims to enhance clinical and payer expertise, supporting the strategy for broader adoption within hospital systems [8] Management's Comments on Operating Environment and Future Outlook - Management emphasized the importance of disciplined execution and operational excellence to build value for shareholders and customers [12] - The company plans to focus on a handful of states for CompuFlow's rollout, ensuring proper data collection for Medicare reimbursement [21][22] Other Important Information - As of September 30, 2025, the company had cash and cash equivalents of approximately $1.3 million and working capital of approximately $3.1 million [11] Q&A Session Summary Question: How to convince dental clinics to invest in new equipment? - Management acknowledged the need to reconnect with old customers and expand digital marketing efforts to raise awareness about the benefits of their products [15][16] Question: Update on the medical side and broader commercialization plans? - The focus is on supporting current clinics using CompuFlow and collecting data for Medicare reimbursement, with plans for broader commercialization in the near future [21][22] Question: Impact of tariffs on supply chain and customer behavior? - Management reported minimal impact from tariffs and is considering a bonded warehouse in the U.S. to mitigate potential issues [29] Question: Structure of the salesforce and reimbursement specialists? - The company plans to ramp up the salesforce and is considering pursuing reimbursement codes for pediatric use [31] Question: Is there a seasonality pattern in sales? - Management indicated that the business is steady without significant seasonal fluctuations, expecting a similar performance in Q4 [32] Question: Future prospects and challenges for Milestone Scientific? - Management acknowledged past challenges but emphasized a focused approach with strong technology and a structured plan for growth [39][40] Question: Current cash position and capital needs? - The company has sufficient cash to operate for several quarters and is looking for opportunities to improve its financial position [47]

Financial Data and Key Metrics Changes - For Q3 2025, revenue was $2.4 million, a slight decrease from $2.5 million in Q3 2024. For the nine months ended September 30, 2025, revenue was $6.9 million, compared to $6.6 million for the same period in 2024 [10] - Operating expenses were reduced by over $500,000 compared to the same period last year, reflecting disciplined cost management [5][10] - As of September 30, 2025, cash and cash equivalents were approximately $1.3 million, with working capital of approximately $3.1 million [11] Business Line Data and Key Metrics Changes - In the dental segment, international sales increased year-over-year, partially offsetting a decline in domestic revenue [7] - Utilization of CompuFlow disposables rebounded slightly, indicating a re-engagement with current customers [7] Market Data and Key Metrics Changes - The company has a market share of approximately 1.5%-2% in both domestic and international markets, indicating significant room for growth [16] Company Strategy and Development Direction - The company is focused on three strategic priorities: streamlining operations, strengthening commercial execution in dental and medical sectors, and advancing reimbursement strategies for CompuFlow [6][12] - The addition of Dr. Dawood Syed to the board aims to enhance clinical and payer expertise, supporting the strategy for broader adoption within hospital systems [8] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's technology and the need for a structured approach to sales and reimbursement strategies [39][40] - The focus is on disciplined execution and operational excellence to build long-term shareholder value [12][50] Other Important Information - The company is enhancing its omnichannel marketing strategy to increase brand visibility and customer engagement [9] Q&A Session Summary Question: How to convince dental clinics to invest in new equipment? - Management acknowledged the need to reconnect with old customers and expand digital marketing efforts to raise awareness about the benefits of their products [15][16] Question: Update on the medical side and broader commercialization plans? - The company is focusing on a few jurisdictions for CompuFlow and plans to collect data meticulously to support Medicare reimbursement [21][22] Question: Impact of tariffs on supply chain and customer behavior? - Management reported minimal impact from tariffs and is considering a bonded warehouse in the U.S. to mitigate potential issues [29] Question: Structure of the salesforce and reimbursement specialists? - The company plans to ramp up its sales organization and is considering pursuing reimbursement codes for pediatric use [30][31] Question: Is there a seasonality pattern in sales? - Management indicated that the business is steady without significant seasonal fluctuations, expecting a similar performance in Q4 [32] Question: Long-term outlook and challenges faced? - Management emphasized the importance of having a structured approach to sales and reimbursement to ensure sustainable growth [39][40] Question: Current cash position and need for capital? - The company has sufficient cash to operate for several quarters and is looking for opportunities to improve its financial position [47]

Financial Data and Key Metrics Changes - For Q3 2025, revenue was $2.4 million, a slight decrease from $2.5 million in Q3 2024. For the nine months ended September 30, 2025, revenue was $6.9 million, compared to $6.6 million for the same period in 2024 [10] - Gross profit for the nine months ended September 30, 2025, was approximately $4.9 million, reflecting no material year-over-year change [10] - Operating expenses were approximately $1.1 million for Q3 2025, a reduction of over $500,000 compared to the same period last year [5][10] Business Line Data and Key Metrics Changes - In the dental segment, international sales increased year-over-year, partially offsetting a decline in domestic revenue [6] - Utilization of CompuFlow disposables rebounded slightly, indicating a re-engagement with current customers [6][8] Market Data and Key Metrics Changes - The company has a market share of approximately 1.5%-2% in both domestic and international markets, indicating significant room for growth [17] - The company is focusing on expanding its commercial coverage footprint in key jurisdictions like New Jersey, Texas, and Florida [8][24] Company Strategy and Development Direction - The company is executing a transformational strategy focused on streamlining operations, strengthening commercial execution, and advancing reimbursement strategies for CompuFlow [5][12] - The addition of Dr. Dawood Syed to the board aims to enhance clinical and payer expertise, supporting the strategy for broader adoption within hospital systems [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's technology and emphasized the need for a structured approach to sales and reimbursement to ensure sustainable growth [40][41] - The focus remains on disciplined execution, operational excellence, and building value for shareholders, customers, and patients [12][54] Other Important Information - As of September 30, 2025, the company had cash and cash equivalents of approximately $1.3 million and working capital of approximately $3.1 million [11] - The company is considering establishing a bonded warehouse in the U.S. to mitigate potential tariff impacts [29] Q&A Session Summary Question: How to convince dental clinics to invest in new equipment? - Management acknowledged the challenge and emphasized the need for better education and marketing to increase awareness of the product's benefits [15][17] Question: What is the plan for broader commercialization of CompuFlow? - The focus is on a few key states and jurisdictions, with plans to collect data meticulously to support Medicare reimbursement [21][22] Question: How is the salesforce structured? - The company plans to ramp up the salesforce and is considering adding reimbursement specialists to enhance sales efforts [31][32] Question: Is there a seasonality pattern in sales? - Management indicated that the business is steady without significant seasonal fluctuations, expecting a similar performance in Q4 [33] Question: What is the current cash position and need for capital? - The company has sufficient cash to operate for several quarters and is looking for opportunities to improve its financial position if necessary [50]

Group 1: RLX Technology Inc - RLX Technology Inc reported quarterly earnings of 3 cents per share on sales of $158.600 million [1] - Shares of RLX Technology rose 6% to $2.47 in pre-market trading following the earnings report [1] Group 2: Other Stocks in Pre-Market Trading - Cidara Therapeutics, Inc. surged 92% to $203.50 after a Schedule 13D Amendment revealed beneficial ownership of 3.37 million shares [4] - Binah Capital Group, Inc. gained 52.2% to $2.17 after posting stronger-than-expected third-quarter results [4] - Expion360 Inc. rose 42.4% to $1.81 following its third-quarter results [4] - Aspire Biopharma Holdings, Inc. surged 31.2% to $0.1380 in pre-market trading [4] - Invivyd, Inc. gained 28.8% to $2.28 after reporting better-than-expected third-quarter financial results [4] - Milestone Scientific Inc. surged 26.3% to $0.4801 after reporting better-than-expected third-quarter sales [4] - Lazydays Holdings, Inc. gained 23.3% to $1.85 after a previous surge [4] - Omeros Corp gained 12.5% to $7.08 following a narrower-than-expected quarterly loss [4] - Nouveau Monde Graphite Inc rose 10% to $3.25 after a decline the previous day [4] Group 3: Declining Stocks in Pre-Market Trading - TSS Inc tumbled 40.2% to $9.10 after reporting a year-over-year decrease in third-quarter results [4] - enVVeno Medical Corp declined 35.8% to $0.42 after an unfavorable FDA appeal decision [4] - Nuvve Holding Corp fell 29.3% to $0.34 after announcing third-quarter results [4] - ESS Tech Inc shares dipped 24.2% to $3.22 after reporting weak quarterly sales [4] - Direct Digital Holdings Inc fell 18.8% to $0.23 after a significant gain the previous day [4] - StubHub Holdings Inc fell 18.8% to $15.28 after worse-than-expected third-quarter EPS results [4] - Mangoceuticals Inc dipped 17.7% to $0.98 after a decline the previous day [4] - Red Cat Holdings Inc dipped 15.1% to $6.57 after worse-than-expected financial results and a lowered FY25 sales guidance [4] - WhiteFiber Inc fell 13.4% to $17.21 after reporting worse-than-expected financial results [4] - Sobr Safe Inc fell 12.4% to $2.21 after a decline the previous day [4]

Core Insights - Milestone Scientific Inc. reported a significant increase in share price, surging 35.67% in after-hours trading to $0.52 following the release of its third-quarter results, which showed lower costs and improved losses [1] Financial Performance - The company reduced its operating expenses by over $500,000 in Q3 compared to the same period last year, contributing to improved margins [2] - Operating loss decreased by 23% to approximately $1.1 million from $1.5 million a year earlier, while net loss narrowed to $1.2 million, or $0.01 per share, compared to $1.5 million, or $0.02 per share, in Q3 2024 [3] - Third-quarter revenue was about $2.4 million, slightly down from $2.5 million in the same quarter last year, with lower domestic dental sales offset by stronger international demand and steady recurring medical revenue [4] - For the first nine months of the year, revenue increased by 5% to $6.9 million from $6.6 million, driven by growth in international dental markets and higher recurring revenue in the medical segment [4] Strategic Developments - The CEO highlighted the company's positive outlook on growing utilization and recurring revenue from CompuFlo disposables, alongside advancements in its reimbursement strategy, which includes recent Medicare payment-rate assignments and expanded commercial coverage [5] Stock Performance - Year-to-date, Milestone Scientific's shares have declined by 59.61%, with stock prices fluctuating between $0.35 and $1.39 over the past year, and a market capitalization of approximately $29.8 million [6]

Revenue Performance - Total product sales for the three months ended September 30, 2025, were approximately $2.36 million, a decrease of about $154,000 or 6% compared to $2.51 million in the same period of 2024[116] - Dental revenue for the three months ended September 30, 2025, was approximately $2.32 million, down $149,212 from $2.47 million in the prior year[115] - International dental revenue decreased to approximately $1.0 million in Q3 2025, compared to $1.2 million in Q3 2024, a reduction of approximately $242,000 or 20%[119] - Revenue from Dental Service Organizations (DSOs), government agencies, and dental schools increased slightly to approximately $83,000 for the three months ended September 30, 2025, compared to $81,000 in the prior-year period[117] - E-commerce dental revenue totaled approximately $1.0 million for the three months ended September 30, 2025, compared to $1.1 million for the same period in 2024, a decrease of approximately $105,000 or 9%[118] - Consolidated revenue for the nine months ended September 30, 2025, was approximately $6.9 million, representing an increase of approximately $300,000, or 5%, compared to $6.6 million in 2024[130] - International revenue for the nine months ended September 30, 2025, was approximately $2.9 million, an increase of approximately $211,000, or 8%, compared to $2.7 million in 2024[133] Profitability and Loss - Gross profit for the three months ended September 30, 2025, was $1.64 million, compared to $1.84 million in the same period of 2024[114] - The net loss for the three months ended September 30, 2025, was $1.15 million, compared to a net loss of $1.46 million in the same period of 2024[114] - The loss from operations for the three months ended September 30, 2025, was approximately $1.1 million, an improvement of approximately $335,000, or 22%, compared to $1.5 million in 2024[128] - The loss from operations for the nine months ended September 30, 2025, was approximately $4.6 million, an improvement of approximately $98,000, or 2%, compared to $4.7 million in 2024[141] Expenses - Operating expenses for the three months ended September 30, 2025, totaled $2.78 million, down from $3.31 million in the prior year[114] - Consolidated selling, general, and administrative (SG&A) expenses for the three months ended September 30, 2025, were approximately $2.7 million, a decrease of approximately $325,000, or 10%, compared to $3.1 million in 2024[124] - Consolidated research and development (R&D) expenses for the three months ended September 30, 2025, were approximately $16,000, representing a decrease of approximately $216,000, or 93%, compared to $232,000 in 2024[126] - Consolidated research and development (R&D) expenses for the nine months ended September 30, 2025, were approximately $437,000, a decrease of approximately $204,000, or 32%, compared to $641,000 in 2024[138] Cash Flow and Financial Position - Net cash provided by financing activities increased by approximately $553,000 for the nine months ended September 30, 2025, compared to the same period in 2024, primarily due to the issuance of $800,000 in convertible notes payable during 2025[146] - As of September 30, 2025, the Company had cash and cash equivalents of approximately $1.3 million and working capital of approximately $3.1 million[149] - Net cash flows used in operating activities were approximately $2.7 million for the nine months ended September 30, 2025, compared to $1.4 million for the same period in 2024[149] Going Concern and Future Outlook - Management has concluded that substantial doubt exists about the Company's ability to continue as a going concern for a period of one year from the date these unaudited condensed financial statements are issued[149] - The Company is actively pursuing additional sources of funding through equity and debt financing to support its operating plan[150] - The continuation of operations is dependent upon the Company's ability to raise additional capital and achieve sustained profitability[151] - The Company continues to focus on generating positive cash flow from operations by increasing revenue from its dental business and expanding sales of medical devices and disposables[151] Market Developments - The company has received FDA clearance for the CompuFlo® Epidural Computer Controlled Anesthesia System, expanding its market potential in medical applications[109] - The recent issuance of a CPT code by the American Medical Association enhances reimbursement potential for epidural procedures using the CompuFlo® system, supporting broader adoption in the U.S.[110] - Sales in China for the three months ended September 30, 2025, were approximately $200,000, compared to no sales in the same period of 2024, reflecting successful reestablishment of operations[120] - Revenue from the medical segment totaled approximately $41,000 for the three months ended September 30, 2025, a decrease of approximately $6,000, or 13%, compared to the same period in 2024[121] Consolidated Financial Performance - Consolidated gross profit for the three months ended September 30, 2025, was approximately $1.6 million, representing a decrease of approximately $195,000, or 11%, compared to $1.8 million in 2024[123]

Core Insights - Milestone Scientific Inc. reported continued progress in operational transformation and growth strategy across its dental and medical segments, with a focus on building a leaner organization for sustained growth and improved profitability [1][2]. Financial Performance - For Q3 2025, revenues were approximately $2.4 million, a slight decrease from $2.5 million in Q3 2024, primarily due to lower domestic dental sales, partially offset by higher international dental sales and recurring medical revenue [3]. - Gross profit for Q3 2025 was approximately $1.6 million, or 70% of revenue, compared to $1.8 million, or 73% of revenue, in Q3 2024 [3]. - The operating loss for Q3 2025 was approximately $(1.1) million, an improvement of approximately $0.3 million, or 23%, from $(1.5) million in Q3 2024, attributed to lower selling, general, and administrative expenses [3]. - The net loss for Q3 2025 was approximately $(1.2) million, or $(0.01) per share, compared to a net loss of $(1.5) million, or $(0.02) per share, in Q3 2024 [3]. Year-to-Date Results - For the nine months ended September 30, 2025, revenues were approximately $6.9 million, an increase of approximately $0.3 million, or 5%, from $6.6 million in the same period of 2024, driven by growth in international dental sales and higher recurring revenue from the medical segment [4]. - Gross profit for the nine months ended September 30, 2025, was approximately $4.9 million, or 71% of revenue, consistent with the previous year [4]. - The operating loss for the nine months ended September 30, 2025, was approximately $(4.6) million, slightly improved from $(4.7) million in the same period of 2024 [4]. - The net loss for the nine months ended September 30, 2025, was approximately $(4.6) million, or $(0.06) per share, compared to a net loss of $(2.7) million, or $(0.03) per share, in the same period of 2024 [4]. Cash Position - As of September 30, 2025, the company reported cash and cash equivalents of approximately $1.3 million and working capital of approximately $3.1 million [5]. Strategic Initiatives - The company is expanding its direct sales programs in North America and securing new international registrations for its STA® Single Tooth Anesthesia System, while enhancing its omnichannel digital marketing strategy [2]. - There is growing utilization and recurring revenue from CompuFlo® disposables, with increasing interest from hospitals and international distributors [2]. - The company is advancing its reimbursement strategy for CompuFlo®, focusing on securing Medicare payment-rate assignments and expanding commercial coverage, which are seen as key enablers for broader adoption [2].